Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531539 | 0.84 | EPHX2 (0.41) | GPR35PTPN1KMT2ATP53EPHX1 | |
| SCHEMBL2518709 | 0.81 | SMN1; SMN2 (0.65) | MEN1KMT2ATP53EPHX1TSHR | |
| SCHEMBL3911427 | 0.80 | TDP1 (0.54) | GPR35KMT2ASMN1; SMN2 | |
| SCHEMBL50031 | 0.78 | HSD17B10 (0.57) | MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL789578 | 0.78 | GAA (0.50) | MEN1KMT2ATP53EPHX1TSHR | |
| SCHEMBL750529 | 0.78 | KCNK3 (0.59) | PTPN1MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL7515812 | 0.77 | DHODH (0.61) | MEN1KMT2ATSHR | |
| SCHEMBL7515816 | 0.77 | DHODH (0.61) | MEN1KMT2ATSHR | |
| SCHEMBL616739 | 0.77 | PTPN11 (0.75) | GPR35PTPN11PTPN1MEN1KMT2A | |
| SCHEMBL1418819 | 0.76 | SCN1A (0.40) | MEN1KMT2AEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-0028351-B1 | REACTIVE DYESTUFFS AND THEIR USE IN DYEING MATERIALS CONTAINING OH OR NH | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| EP-0028351-A2 | Reactive dyestuffs and their use in dyeing materials containing OH or NH | BAYER AG (DE) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | GPR35 240/4885PTPN11 1622/4885PTPN1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.